Baxter Plans $146.5 Million Investment In China Dialysis-Related Plants
This article was originally published in PharmAsia News
Executive Summary
Baxter International plans to invest $146.5 million in China to increase production capacity for dialysis products at four of its plants. The U.S.-based company plans to expand its products relying on intravenous and peritoneal solutions to meet Baxter China General Manager Paul Vibert's goal of double-digit sales growth this year. Baxter has plants in Guangzhou, Suzhou, Tianjin and Shanghai. (Click here for more